Viedoc Technologies, a provider of e-clinical software for the global clinical trials industry, has announced several initiatives to expand its participation in the US market to meet the growing demand. The company aims to capitalise on the significant growth it has experienced in the United States over the past 12 months, with 37% of all new customers globally in 2023 based in the declining early-phase market.

The US clinical trials industry is growing rapidly. Viedoc has nearly 100 clients in the US, making it the company’s most exciting market for expansion. 2023 was a landmark year, with revenue growth for the company in the US over the past 12 months reaching 27%.

Clinical trials in the US follow rigorous protocols and are regulated by the FDA to ensure the ethical treatment of participants and the reliability of the data generated. Trials are a fundamental part of the US healthcare system and are crucial in advancing medical research and improving patient outcomes.

The US market is paramount in advancing medical knowledge, improving patient treatment and driving innovation. It serves as the cornerstone for developing and approving new drugs, therapies, and medical interventions, playing a pivotal role in ensuring the safety and efficacy of healthcare products. It contributes significantly to the global economy through job creation, research and development investments, and the growth of related industries. It fosters a culture of innovation that can lead to the establishment of new biotech and pharmaceutical companies.

Viedoc first entered the US market in the late 2010s. By 2020, with a limited number of customers in the region but indications of significant potential, efforts were made to reinforce business development by appointing a dedicated US team. Today, Viedoc has established many key functions in the US, including its Professional Services team.

Initiatives to expand Viedoc’s participation in the US market include:

  • US HQ office location: Viedoc is expanding its presence in the region with a new office in Raleigh, North Carolina, where more than 150 clinical research companies and universities employ 27,000 individuals, with thousands more working globally. These organisations are crucial in supporting pharmaceutical, biotech and medical device companies and research institutions, offering a comprehensive array of services. Viedoc boasts full business development capabilities across all time zones, and this new capacity enables the company to localise operations for US clients further.
  • Key executive hire: Extending its localisation in the US market, Viedoc has appointed Bob Egner as Chief Marketing Officer. He has held leadership roles in marketing, product management, and business development for firms across the globe. With a particular emphasis on helping Europe-based B2B software companies localise and expand in the US market, Egner has made notable contributions to companies like Outpost24, Episerver (now Optimizely), Check Point Software Technologies, and Pointsec, highlighting his commitment to innovation.
  • New data privacy processes: Viedoc has adapted current data privacy processes to US market requirements by adding SOC2 assessment — a voluntary compliance standard developed by the American Institute of CPAs (AICPA) on top of its established ISO 27001 certification. Contact Viedoc for more information about the newly completed audit.
  • Scaling up delivery capability: By expanding a US cloud instance to deliver its top-rated eClinical solutions with a Software as a Service (SaaS) operational model, Viedoc now provides the reach and scale needed to meet the world’s heaviest clinical trial volume that is found in the US market. New solutions have been recently added to the platform, including eTMF, eISF, enhanced reporting and RTSM.

“We can already see the positive impact we’ve had in the US challenging the legacy providers and current best practices. Now, we are reinforcing our commitment to advancing clinical research in the United States. Viedoc is dedicated to empowering the growth of the US clinical trials industry, fostering innovation, and ensuring the highest standards of data integrity. Our strategic initiatives underscore our passion for making a meaningful impact on healthcare, driving us closer to our vision of delivering necessary treatments to those who need them faster than ever before,” says Mats Klaar, CEO of Viedoc.